|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
IL-6 concentration in the plasma of <i>TNFα</i> A-allele carriers at months 1 and 12 after CABG was higher in the HF group compared to the non-HF group (1 month after CABG: 5.3 ± 3.4 vs. 3.1 ± 2.9, p<0.05; 12 months after CABG: 4.2 ± 3,9 vs. 1.4 ± 1.2, p<0.01, respectively).
|
31275366 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Maternal serum concentrations of tumor necrosis factor-α, interleukin-6, soluble Fas ligand, transforming growth factor-α, and vascular endothelial growth factor-D were significantly higher when fetuses had heart failure than when they did not (P < .05), whereas maternal serum concentrations of heparin-binding epidermal growth factor-like growth factor were significantly lower when fetuses had heart failure than when they did not (P < .05).
|
30273582 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mechanistic studies in vitro demonstrated that T lymphocyte culture supernatants stimulated by β<sub>1</sub>-AAmAb caused direct damage in the cardiomyocytes, and β<sub>1</sub>-AAmAb promoted proliferation of T lymphocytes isolated from patients with heart failure and increased IL-6 release.
|
30747396 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, RORα protects against ANG II-mediated pathological hypertrophy and heart failure by suppressing the IL-6-STAT3 pathway and enhancing mitochondrial function.
|
30387679 |
2019 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Both adrenergic stimulation and high levels of interleukin-6 (IL-6) indicate an unfavorable outcome in patients with myocardial infarction or heart failure.
|
31749886 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results exhibited that YQFM significantly mitigated CAL-induced HF via meliorating the left ventricular contractile function and reducing the serum content of creatine kinase MB (CK-MB), aspartate aminotransferase (AST), interleukin-6 (IL-6), troponin (Tn), myosin, myoglobin (MYO) and myocilin (MYOC).
|
31505423 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The multivariable logistic regression showed that IL-1β [relative ratio (RR) = 1.08, 95% CI: 1.02-1.15, <i>P</i> = 0.010], IL-6 (RR = 1.03, 95% CI: 1.01-1.06, <i>P</i> = 0.016), PTX-3 (RR = 1.31, 95% CI: 1.11-1.55, <i>P</i> = 0.001), and ANGPTL-4 (RR = 1.05, 95% CI: 1.02-1.07, <i>P</i> < 0.001) were independently associated with HF, while IL-6 (RR = 1.03, 95% CI: 1.01-1.04, <i>P</i> = 0.019), PTX-3 (RR = 1.23, 95% CI: 1.06-1.43, <i>P</i> = 0.007), and ANGPTL-4 (RR = 1.03, 95% CI: 1.01-1.06, <i>P</i> = 0.005) were independently associated with the HF subtype.
|
31105751 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together with possible involvement of interleukin-6 in the pathogenesis of heart failure and muscle wasting, inhibition of interleukin-6 receptor signalling by tocilizumab may be a safe and reasonable approach in the treatment of active TA with heart failure and muscle wasting.
|
31297975 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, little is known regarding the association between IL-6 and clinical characteristics, outcomes and other inflammatory biomarkers in HF.
|
31087601 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The three biomarkers were shown to be good predictors of post-STEMI HF (IL-6: AUC 0.786, P=0.002; VCAM-1: AUC 0.797, P=0.001; and ICAM-1: AUC 0.825, P<0.0001), with the respective cutoff points being calculated based on the best sensitivity and specificity indexes (IL-6: 8.67 pg/mL; VCAM-1: 1501.42 ng/mL; and ICAM-1: 1262.38 ng/mL).
|
31778438 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
A total of 559 Danish subjects with severe chronic HF enrolled in the previously reported Echocardiography and Heart Outcome Study were genotyped for three SNPs in IL6, nine in the IL-6 receptor gene (IL6R), and two in the IL-6 signal transducer gene (IL6ST).
|
30651573 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that cardiac chagasic patients have an increased percentage of inflammatory monocytes and produce more IL-6, a biomarker of heart failure and left ventricular dysfunction, whereas asymptomatic chagasic individuals present a higher percentage of reparative monocytes and CCL17.
|
31379862 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
IL6 is strongly and independently associated with ASCVD events, HF, and all-cause mortality, particularly among statin users.
|
30312930 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Specific matrix metalloproteinases (MMP-2, MMP-9) and inflammatory biomarkers (hsCRP, IL-6) were found to be consistently up-regulated in severe mitral valve regurgitation (MR) and are associated with mortality in heart failure patients.
|
29663512 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
RGD |
This study examined the effects of exercise training (ExT) upon concentration of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and interleukin-10 (IL-10) in the gastrocnemius of rats with heart failure (HF) induced by left coronary artery ligation.
|
28939262 |
2018 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The percentage of human leukocyte antigen-D-related (HLA-DR)<sup>-</sup>CD33<sup>+</sup>CD11b<sup>+</sup> MDSCs in the blood of patients with HF was significantly increased and positively correlated with disease severity and increased plasma levels of cytokines, including interleukin-6, interleukin-10, and transforming growth factor-β.
|
29437117 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Studies have shown co-relationship between severity of heart failure and levels of the proinflammatory cytokine TNFα and one of its secondary mediators interleukin-6 (IL-6), suggesting their potential as biomarkers.
|
30259192 |
2018 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Higher initial levels of IL-6 in HF patients were correlated with longer distance in 6MWT one month after surgery and lower PPAR<i>γ</i> expression.
|
29093735 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
After further adjustment for biomarkers (high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A<sub>2</sub> activity, high-sensitivity troponin I, and B-type natriuretic peptide), IL-6 remained significantly associated with the risk of major adverse cardiovascular events (adj HR Q4:Q1 1.43, 95% CI 1.09-1.88) and cardiovascular death or heart failure (adj HR 1.79, 95% CI 1.22-2.63).
|
29066436 |
2017 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
After adjusting for eGFR, albuminuria, and other traditional cardiovascular risk factors, anemia (1.37, 95% CI 1.09, 1.72, <i>P</i>=0.006), insulin resistance (1.16, 95% CI 1.04, 1.28, <i>P</i>=0.006), hemoglobin A1c (1.27, 95% CI 1.14, 1.41, <i>P</i><0.001), interleukin-6 (1.15, 95% CI 1.05, 1.25, <i>P</i>=0.002), and tumor necrosis factor-α (1.10, 95% CI 1.00, 1.21, <i>P</i>=0.05) were all significantly and directly associated with incidence of heart failure.
|
28515118 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In women with signs and symptoms of ischemia, non-obstructive CAD and preserved EF, elevated IL-6 predicted HF hospitalization and all-cause mortality, while SAA level was only associated with all-cause mortality.
|
28542263 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The results of the study demonstrated that IL‑6 contributed to the progression of HF via the AT1‑R pathway.
|
28440487 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study examined the individual and combined effect of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), interleukin-6 (IL-6), and hs-CRP on the prediction of heart failure incidence or progression in patients with type 2 diabetes.
|
28684396 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Proinflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor α (TNFα) have long been implicated in cardiovascular risk and considered to be a major underlying cause for heart failure (HF).
|
28763371 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Presence of metabolic syndrome (MS) and its components, presence of heart failure, severity of CAD symptoms, severe past ventricular arrhythmia (sustained ventricular tachycardia [sVT] or ventricular fibrillation [VF]), lower left ventricle ejection fraction, higher left ventricle mass index, higher end-diastolic volume and higher number of smoking pack-years were significantly associated with higher WBC, CRP and IL-6.
|
26864064 |
2016 |